Author name: Claritas Rx

As genetic testing becomes more common, it also generates fruitful data for specialty pharma.

There’s lots of obstacles to ensure patients can access clinically appropriate therapy, and even once they do start treatment, questions arise as to whether they’ll stay on the treatment, and even how effective it is. Solving abandonment and discontinuation in specialty drugs can be nonviable, unless you have the in-depth data to identify the cause,

Specialty drug market growth calls for greater attention to data resources. Here’s why.

A successful product launch requires all hands on deck. Here’s how to foster communication with the right tools.

What metrics help government payers understand value and cost controls for rare disease therapies?

Comparing drug efficacy is essential — and backing it up with quantifiable data is a must.

To help patients adhere to treatment protocols, collect patient-level data.